Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology: Calcineurin inhibitors and sirolimus in dermatology
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Controlled trials and clinical experience indicate that systemic cyclosporin A and tacrolimus are effective treatments for psoriasis, and that cyclosporin A also improves atopic eczema. A variety of other inflammatory and non-inflammatory skin diseases are probably also responsive to these drugs. However, the widespread and longer-term use of cyclosporin A and tacrolimus are limited by side effects. The molecular mechanisms of action of cyclosporin A, tacrolimus and a related drug, sirolimus, have been well defined in T cells and involve inhibition of critical signalling pathways that regulate T cell activation. For example cyclosporin and tacrolimus inhibit calcineurin phosphatase activity and thereby inhibit activation of the transcription factor NFAT. The therapeutic efficacy of topical calcineurin inhibitors in atopic eczema have restimulated interest in the mechanism of action of these drugs in skin disease. Recently the expression pattern of calcineurin and NFAT has been defined in non-immune tissues including the akin. The relevance of this to the mechanism of action of systemic and topical calcineurin inhibitors and sirolimus in skin disorders is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
The transcription factor NF-ATc is essential for cardiac valve formation
Ranger, A. M., Grusby, M. J., Hodge, M. R., Gravallese, E. M., de la Brousse, F. C., Hoey, T., Mickanin, C., Baldwin, H. S., & Glimcher, L. H. (1998) · Nature · doi:10.1038/32426 · Cited by 586
Cited by
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
“Another calcineurin inhibitor is tacrolimus, which is 50–100 times more potent than cyclosporin A (88).”
BackgroundJuvvadi, P. R., Lamoth, F., & Steinbach, W. J. (2014) · Fungal Biology Reviews · doi:10.1016/j.fbr.2014.02.004 · Cited by 116
Li, W.-W., Yang, Y., Shi, X.-Y., Guo, T.-Z., Guang, Q., Kingery, W. S., Herzenberg, L. A., & Clark, J. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.029 · Cited by 18
“Without activation of NFAT, T cells, particularly Tfh cells, lose function (Reynolds and Al-Daraji, 2002).”
Background
Metadata
- Authors
- Reynolds, N. J., & Al-Daraji, W. I.
- Venue
- Clinical and Experimental Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10
- Volume
- 27
- Issue
- 7
- Pages
- 555-561
- ISSN
- 0307-6938 (ISSN-L)
- OpenAlex
- W2021947384
- Cited by
- 118
- References
- 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology: Calcineurin inhibitors and sirolimus in dermatology. https://app.cochat.ai/papers/10.1046/j.1365-2230.2002.01148.x
- The paper
- Reynolds, N. J., & Al-Daraji, W. I. (2002). Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology: Calcineurin inhibitors and sirolimus in dermatology. Clinical and Experimental Dermatology. https://doi.org/10.1046/j.1365-2230.2002.01148.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.